Gilead Sciences
Gilead Sciences returns on capital
Annual and trailing 12-month returns on invested capital, equity and assets.
ROIC
% · Annual / TTM
ROCE
% · Annual / TTM
ROIIC
% · Annual / TTM
ROE
% · Annual / TTM
ROA
% · Annual / TTM
ROIC − WACC
Percentage points · Scenario
Quarterly data
| Fiscal period | Ended | ROIC% | ROCE% | ROIIC% | ROE% | ROA% | ROIC − WACCPercentage points |
|---|---|---|---|---|---|---|---|
| FY 2026 Q2 | Jun 30, 2026 | — | -6.03% | — | -20.57% | -6.17% | — |
| FY 2026 Q1 | Mar 31, 2026 | — | 22.82% | — | 43.19% | 16.35% | — |
| FY 2025 Q4 | Dec 31, 2025 | — | 21.28% | — | 40.49% | 14.42% | — |
| FY 2025 Q3 | Sep 30, 2025 | — | 23.56% | — | 40.53% | 14.35% | — |
| FY 2025 Q2 | Jun 30, 2025 | — | 18.44% | — | 33.26% | 11.55% | — |
| FY 2025 Q1 | Mar 31, 2025 | — | 18.82% | — | 32.51% | 10.58% | — |
| FY 2024 Q4 | Dec 31, 2024 | — | 3.4% | — | 2.28% | 0.79% | — |
| FY 2024 Q3 | Sep 30, 2024 | — | 1.76% | — | 0.62% | 0.22% | — |
| FY 2024 Q2 | Jun 30, 2024 | — | 5.61% | — | 5.34% | 1.82% | — |
| FY 2024 Q1 | Mar 31, 2024 | — | 3.34% | — | 2.51% | 0.82% | — |
| FY 2023 Q4 | Dec 31, 2023 | — | 14.8% | — | 25.71% | 9.04% | — |
| FY 2023 Q3 | Sep 30, 2023 | — | 16.11% | — | 27.08% | 9.41% | — |
| FY 2023 Q2 | Jun 30, 2023 | — | 16.61% | — | 26.5% | 8.76% | — |
| FY 2023 Q1 | Mar 31, 2023 | — | 16.7% | — | 27.28% | 8.94% | — |
| FY 2022 Q4 | Dec 31, 2022 | 13.8% | 13.54% | — | 21.71% | 7% | 5.9 pp |
| FY 2022 Q3 | Sep 30, 2022 | — | 11.02% | — | 15.67% | 5.14% | — |
| FY 2022 Q2 | Jun 30, 2022 | — | 12.58% | — | 20.72% | 6.32% | — |
| FY 2022 Q1 | Mar 31, 2022 | — | 12.87% | — | 23.23% | 6.92% | — |
| FY 2021 Q4 | Dec 31, 2021 | 17.27% | 17.5% | — | 31.7% | 9.13% | 9.4 pp |
| FY 2021 Q3 | Sep 30, 2021 | — | 21.49% | — | 38% | 11.56% | — |
| FY 2021 Q2 | Jun 30, 2021 | — | 18.98% | — | 27.36% | 8.33% | — |
| FY 2021 Q1 | Mar 31, 2021 | — | 8.39% | — | 1.47% | 0.47% | — |
| FY 2020 Q4 | Dec 31, 2020 | 0.55% | 7.48% | — | 0.6% | 0.19% | -7.4 pp |
| FY 2020 Q3 | Sep 30, 2020 | — | 4.98% | — | 6.67% | 2.11% | — |
| FY 2020 Q2 | Jun 30, 2020 | — | -1.93% | — | -1.26% | -0.43% | — |
| FY 2020 Q1 | Mar 31, 2020 | — | 8.54% | — | 22.55% | 8.1% | — |
| FY 2019 Q4 | Dec 31, 2019 | — | 8.17% | — | 24.53% | 8.6% | — |
| FY 2019 Q3 | Sep 30, 2019 | — | 8.36% | — | 12.39% | 4.36% | — |
| FY 2019 Q2 | Jun 30, 2019 | 15.81% | 15.52% | 10,491.45% | 26.89% | 9.26% | 7.9 pp |
| FY 2019 Q1 | Mar 31, 2019 | 16.29% | 15.32% | — | 27.7% | 9.19% | 8.4 pp |
| FY 2018 Q4 | Dec 31, 2018 | 14.84% | 14.68% | — | 26.08% | 8.14% | 6.9 pp |
| FY 2018 Q3 | Sep 30, 2018 | 4.32% | 17.11% | — | 6.65% | 2.46% | -3.6 pp |
| FY 2018 Q2 | Jun 30, 2018 | 6.07% | 19.84% | — | 9.96% | 3.52% | -1.8 pp |
| FY 2018 Q1 | Mar 31, 2018 | 9.24% | 24.03% | -183.78% | 16.88% | 5.63% | 1.3 pp |
| FY 2017 Q4 | Dec 31, 2017 | 11.55% | 26.55% | -100.98% | 23.53% | 7.27% | 3.7 pp |
| FY 2017 Q3 | Sep 30, 2017 | 30.91% | 31.57% | -42.42% | 55.62% | 19.13% | 23 pp |
| FY 2017 Q2 | Jun 30, 2017 | 34.8% | 36.07% | -47.33% | 63.92% | 22.16% | 26.9 pp |
| FY 2017 Q1 | Mar 31, 2017 | 38.64% | 38.83% | -74.06% | 74.69% | 23.96% | 30.7 pp |
| FY 2016 Q4 | Dec 31, 2016 | 42.21% | 39.31% | -51.34% | 72.16% | 24.81% | 34.3 pp |
| FY 2016 Q3 | Sep 30, 2016 | 51.15% | 44.25% | -20.18% | 87.95% | 28.11% | 43.2 pp |
| FY 2016 Q2 | Jun 30, 2016 | 63.19% | 58.46% | 14.06% | 102.73% | 36.67% | 55.3 pp |
| FY 2016 Q1 | Mar 31, 2016 | 71.42% | 63.39% | 29.08% | 113.42% | 40.29% | 63.5 pp |
| FY 2015 Q4 | Dec 31, 2015 | 79.56% | 62.65% | 60.15% | 106.64% | 41.87% | 71.7 pp |
| FY 2015 Q3 | Sep 30, 2015 | 79.76% | 65.25% | 82.69% | 109.18% | 42.56% | 71.9 pp |
| FY 2015 Q2 | Jun 30, 2015 | 79.49% | 68.08% | 178.6% | 92.92% | 42.75% | 71.6 pp |
| FY 2015 Q1 | Mar 31, 2015 | 79.84% | 66.32% | 439.77% | 92.95% | 42.79% | 71.9 pp |
| FY 2014 Q4 | Dec 31, 2014 | 71.91% | 67.73% | 472.08% | 90.32% | 42.34% | 64 pp |
| FY 2014 Q3 | Sep 30, 2014 | 57.79% | 60.11% | 1,130.15% | 76.94% | 36.66% | 49.9 pp |
| FY 2014 Q2 | Jun 30, 2014 | 45.86% | 45.94% | 629.21% | 54.91% | 27.73% | 38 pp |
| FY 2014 Q1 | Mar 31, 2014 | 28.55% | 32.64% | 293.19% | 38.91% | 18.21% | 20.7 pp |
| FY 2013 Q4 | Dec 31, 2013 | 20.39% | 27.3% | 144.95% | 29.74% | 14.06% | 12.5 pp |
| FY 2013 Q3 | Sep 30, 2013 | 20.09% | 26.29% | 99.6% | 31.26% | 14.03% | 12.2 pp |
| FY 2013 Q2 | Jun 30, 2013 | 19.75% | 26.08% | 43.44% | 30.72% | 13.6% | 11.9 pp |
| FY 2013 Q1 | Mar 31, 2013 | 19.53% | 25.15% | 29.65% | 32.82% | 13.6% | 11.6 pp |
| FY 2012 Q4 | Dec 31, 2012 | 27.79% | 25.25% | -0.33% | 32.3% | 13.45% | 19.9 pp |
| FY 2012 Q3 | Sep 30, 2012 | — | 28.38% | — | 33.75% | 14.79% | — |
| FY 2012 Q2 | Jun 30, 2012 | — | 28.81% | — | 36.3% | 15.36% | — |
| FY 2012 Q1 | Mar 31, 2012 | — | 28.39% | — | 39.07% | 15.73% | — |
| FY 2011 Q4 | Dec 31, 2011 | — | 31.69% | — | 44.49% | 19.41% | — |
| FY 2011 Q3 | Sep 30, 2011 | — | 38.92% | — | 46.82% | 22.97% | — |
| FY 2011 Q2 | Jun 30, 2011 | — | 41.94% | — | 43.33% | 23.56% | — |
| FY 2011 Q1 | Mar 31, 2011 | — | 38.92% | — | 40.6% | 22.78% | — |
| FY 2010 Q4 | Dec 31, 2010 | — | 46.74% | — | 47.44% | 27.25% | — |
| FY 2010 Q3 | Sep 30, 2010 | — | 52.76% | — | 54.15% | 30.15% | — |
| FY 2010 Q2 | Jun 30, 2010 | — | 58.77% | — | 51.77% | 32.22% | — |
| FY 2010 Q1 | Mar 31, 2010 | — | — | — | — | — | — |
| FY 2009 Q4 | Dec 31, 2009 | — | — | — | — | — | — |
| FY 2009 Q3 | Sep 30, 2009 | — | — | — | — | — | — |
| FY 2009 Q2 | Jun 30, 2009 | — | — | — | — | — | — |
Sources and calculations
Financial inputs from company filings. Last checked Oct 18, 2026. A dash means missing inputs or an undefined calculation.
Period changes use the preceding fiscal quarter or year. Percentage changes divide by the absolute prior value; a zero or missing baseline has no percentage change. Percentage metrics show changes in percentage points.
Quarterly returns use trailing 12-month earnings and period-end balances averaged with the same fiscal quarter one year earlier. NOPAT uses the reported effective tax rate only when pretax profit is positive and the rate is between 0 and 100%. WACC starts at 7.9%, rounded from the Pharmaceuticals benchmark in NYU Stern · January 2026. It is an editable US sector proxy applied across history, not a company estimate; foreign reporting currencies also need a currency-specific assessment.
Market prices: Yahoo Finance · GILD, USD. Latest completed close Sep 25, 2026. Price data retrieved Sep 28, 2026.
- ROIC
- NOPAT / average invested capital × 100. NOPAT = operating income × (1 − effective tax rate). Invested capital = equity including noncontrolling interests + debt − cash and equivalents. Average uses period end and one year earlier.
- ROCE
- Operating income / average (assets − current liabilities) × 100, using period end and one year earlier.
- ROIIC
- Year-over-year change in annual/TTM NOPAT / positive year-over-year change in invested capital × 100. Capital reductions and missing inputs yield unavailable values.
- ROE
- Earnings attributable to owners / average equity attributable to owners × 100, using period end and one year earlier.
- ROA
- Net income / average total assets × 100, using period end and one year earlier.
- ROIC − WACC
- ROIC less your WACC assumption, in percentage points. The same scenario rate is applied across history; it is not a reported or historical company WACC.